Cellestia’s clinical study has started

Cellestia’s clinical study has started

8.1.2018 Cellestia Biotech announces the first dosing of cancer patients with the lead compound CB-103 in the first-in-human Phase l – lla clinical study. CB-103 is a proprietary small molecule oncology drug candidate for treatment of solid tumors, lymphomas and leukemias, It features a new mode of action.

read more…